Early Detection Research Network


This biomarker is also known as:
  • CT120.2,
  • transmembrane protein with EGF-like and two follistatin-like domains 2,
  • TMEFF2,
  • TR,
  • TPEF,
  • Hyperplastic polyposis protein 1,
  • tomoregulin,
  • Tomoregulin-2,
  • TENB2,
  • cancer/testis antigen family 120, member 2,
  • HPP1,
  • transmembrane protein TENB2,
  • TR-2,


HPP1 (also called TMEFF2) may be a survival factor for hippocampal and mesencephalic neurons. The shedded form (generated by proteolytic shedding) up-regulates cancer cell proliferation, probably by promoting ERK1/2 phosphorylation. HPP1 is down-regulated in tumor cell lines in response to a high level of methylation in the 5' region. The CpG island methylation correlates with HPP1 silencing in tumor cell lines.


There are no datasets associated with this biomarker.

QA State: Accepted
Type: Genomic

The following organs have data associated with this biomarker…


Phase: Two
QA State: Accepted


Esophageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.

Performance Comment

p16, RUNX3, and TMEFF2 (HPP1) display increasing methylation frequencies in Barrett's esophagus versus esophageal adenocarcinoma. These markers are being further investigated for potential utility in screening Barrett's patients likely to develop esophageal adenocarcinoma.

Supporting Study Data

The following studies/protocols provide evidence supporting TMEFF2 indications for the Esophagus…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Version 5.0.2